Abstract:

Suppose we are interested in estimating an appropriate dose to achieve a therapeutic level for an antibody NME for psoriasis. The question that arises: Can we use data on other compounds to improve the estimates of our NME? The doseresponse curve is estimated using a Hill model. If the parameters of the Hill model can be shown to be shared among compounds, then using prior data would augment the data from the NME and improve the doseresponse estimation. To do this, we need to test the hypothesis that the doseresponse curve is nonflat. Since the null hypothesis is a subset of the parameter space of the alternative, one would expect that the likelihood ratio test (LRT) would be satisfactory. However, this is not the case. We describe why this is not the case, and find that the sampling distribution of the LRT can be expressed as a mixture of nonintegral chisquared random variables. We also show that the LRT does not behave even this well when applied to only summary data. We explore the distribution in this case as well. Finally, if we have time we will show that competitor doseresponse curve provide useful information to help generate dose information on novel NMEs.
